JCG
OREX

JHL Capital Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History

JHL Capital Group’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-24,000
Closed -$1.02M – 31
2014
Q3 		$1.02M Buy
+24,000
New +$1.29M 0.06% 25
2013
Q4 		– Sell
-15,500
Closed -$952K – 37
2013
Q3 		$952K Sell
15,500
-14,500
-48% -$982K 0.16% 19
2013
Q2 		$1.75M Buy
+30,000
New +$1.85M 0.27% 17

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JHL Capital Group's OREX Position: Q4 2014 in Review

JHL Capital Group sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2014, closing a stake of 24,000 shares — an estimated $1.02M sold.

JHL Capital Group first reported a position in OREX in Q2 2013 and held it in 3 quarters. The position peaked at $1.75M in Q2 2013. 147 funds tracked by Wall St. Rank hold OREX as of Q4 2014.

  • JHL Capital Group reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • JHL Capital Group sold 24,000 Orexigen Therapeutics, Inc. shares in Q4 2014, an estimated $1.02M.
  • JHL Capital Group first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 3 quarters.
  • JHL Capital Group's Orexigen Therapeutics, Inc. position peaked at $1.75M in Q2 2013.
  • 147 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2014.

Based on JHL Capital Group's 13F filing for Q4 2014, filed 17 Feb 2015.